Diagnostic Test Accuracy Protocol

Plasma and Cerebrospinal fluid (CSF) Abeta42 for the differential diagnosis of Alzheimer's disease dementia in participants diagnosed with any dementia subtype in a specialist care setting

  1. Michelle Kokkinou1,
  2. Nadja Smailagic2,
  3. Anna H Noel-Storr3,
  4. Chris Hyde4,
  5. Obioha Ukoumunne5,
  6. Rosie E Worrall6,
  7. Anja Hayen7,
  8. Meera Desai8,
  9. Craig Ritchie1,*

Editorial Group: Cochrane Dementia and Cognitive Improvement Group

Published Online: 31 JAN 2014

DOI: 10.1002/14651858.CD010945


How to Cite

Kokkinou M, Smailagic N, Noel-Storr AH, Hyde C, Ukoumunne O, Worrall RE, Hayen A, Desai M, Ritchie C. Plasma and Cerebrospinal fluid (CSF) Abeta42 for the differential diagnosis of Alzheimer's disease dementia in participants diagnosed with any dementia subtype in a specialist care setting (Protocol). Cochrane Database of Systematic Reviews 2014, Issue 1. Art. No.: CD010945. DOI: 10.1002/14651858.CD010945.

Author Information

  1. 1

    Imperial College London, London, UK

  2. 2

    University of Cambridge, Institute of Public Health, Cambridge, UK

  3. 3

    University of Oxford, Radcliffe Department of Medicine, Oxford, UK

  4. 4

    University of Exeter Medical School, University of Exeter, Peninsula Technology Assessment Group (PenTAG), Exeter, UK

  5. 5

    University of Exeter Medical School, University of Exeter, Peninsula CLAHRC, Exeter, Devon, UK

  6. 6

    Oxford University Medical School, Oxford, UK

  7. 7

    University of Oxford, John Radcliffe Hospital, Nuffield Department of Clinical Neurosciences, Oxford, UK

  8. 8

    University of Oxford, Department of Experimental Psychology, Oxford, Oxfordshire, UK

*Craig Ritchie, Imperial College London, London, UK. c.ritchie@imperial.ac.uk.

Publication History

  1. Publication Status: New
  2. Published Online: 31 JAN 2014

SEARCH

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To determine the diagnostic accuracy of the plasma and CSF Abeta42 index tests for distinguishing Alzheimer's disease dementia from each of the other forms of dementia in people who meet the general criteria for a dementia syndrome.

To investigate the heterogeneity of test accuracy in the included studies.

We expect that heterogeneity will be likely and that it will be an important component of the review. The potential sources of heterogeneity, which will be used as a framework for the investigation of heterogeneity, include target population, index test, target disorder and study quality and are detailed in the analysis section.